Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REScUE Open-Label Extension in Crohn's disease
2024-514326-23-00Phase 4Completed
- Sponsor
- Belgian IBD Research and Development
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ustekinumab in Crohn's disease (2 cohorts), sponsored by Belgian IBD Research and Development. Primary endpoint: Sustained steroid-free clinical remission at weeks 56 and 112. Started Jul 2024; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2024-514326-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514326-23-00.